Researchers Tested Potential Vaccine Against SFTS Virus
New mRNA vaccine candidates successfully protected mice from lethal severe fever with thrombocytopenia syndrome.
Updated on Sept. 23, 2026 in Diseases — General
Live Poll
Do you support the early release of medical research before it completes full peer review?
Researchers have developed three lipid nanoparticle-mRNA vaccine candidates to combat severe fever with thrombocytopenia syndrome (SFTS). In a preclinical study, each of these experimental vaccines successfully protected mice from lethal virus challenge.
Why it matters
The SFTS virus carries a high fatality rate of 10% to 27%, and there are currently no approved vaccines available to prevent the disease. Increasing outbreaks underscore the need for effective prophylactic options for this serious viral threat.
In a preclinical study using Ifnar1 mice, researchers tested three mRNA vaccine candidates encoding viral proteins Gn, Gc, and NP. While all candidates offered protection against lethal challenge, those encoding Gn and Gc specifically induced virus-neutralizing activity.
The details
The experimental vaccines use lipid nanoparticles to deliver mRNA that instructs the body to produce specific viral proteins. Researchers determined that the mechanism for the NP-encoded vaccine relies on CD4 cell response, as depleting these cells eliminated the vaccine's protective efficacy. The study involved testing the protective capacity by selectively depleting CD4 and CD8 cells to map the immune pathways required for viral defense.
Timeline
The findings were published on 2026-09-23.
Health Landscape
The application of mRNA technology to the SFTS virus marks a critical shift in the approach to addressing this highly fatal pathogen. This research program builds on established mRNA vaccine development platforms to address infectious diseases that currently lack any standard of care or prevention.
This study is a preclinical development and does not currently impact your personal medical care or treatment options. Always discuss emerging infectious disease concerns or risk factors specific to your travel or location with a primary care physician.
The takeaway
While these preclinical results are promising for future vaccine development, SFTS remains a significant threat with a high mortality rate. If you are living in or traveling to regions where SFTS is present, consult your doctor regarding local tick-borne illness prevention and symptom monitoring.
Further reading
For more on the current landscape of Diseases — General research, see our latest analysis.
Source note: This article includes information reported by Nature.
Live Poll
Do you support the early release of medical research before it completes full peer review?
